You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
With the outbreak of Ebola in West Africa escalating, some scientists think they can save lives by using existing, approved drugs that weren't developed for Ebola but that might nonetheless help patients. Among the proposals being floated are interferon α and statins. The advantage of such existing drugs is that they have been tested for safety, and they are cheap and widely available. But some Ebola scientists oppose trying anything that has not been shown to reduce mortality from Ebola in nonhuman primates. They say that some of the drugs might make the disease worse, and even if they just aren't effective, they might hamper the prospects for the long-term future of more promising drugs developed specifically for Ebola. So far, the World Health Organization appears to be skeptical as well.